{"schema_version":"secwatch.filing_event.v1","accession":"0001127537-23-000014","form_type":"8-K","ticker":"LUNG","cik":"0001127537","company_name":"Pulmonx Corp","filed_at":"2023-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.011786+00:00","generated_at":"2026-06-16T02:39:18.707276+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pulmonx Q1 revenue $14.5M (+35% YoY); reaffirms FY 2023 guidance","bullets":["Worldwide revenue $14.5M, up 35% YoY; U.S. revenue $9.3M (+55% YoY).","Gross margin 73% vs. 75% in Q1 2022; net loss $15.9M ($0.42 per share).","Adjusted EBITDA loss $11.2M vs. $11.8M in prior-year period.","Added 15 new U.S. Zephyr Valve treatment centers in Q1 2023.","Full-year 2023 guidance reaffirmed: revenue $63-65M; gross margin 73-74%."],"urls":{"canonical":"https://secwatch.observer/filing/0001127537-23-000014","json":"https://secwatch.observer/filing/0001127537-23-000014.json","markdown":"https://secwatch.observer/filing/0001127537-23-000014.md","text":"https://secwatch.observer/filing/0001127537-23-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1127537/000112753723000014/0001127537-23-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1127537/000112753723000014/lung-20230502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T02:39:18.707276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"54fcb3d99013047123415a47d7934825cea5d49a","claim":"Pulmonx Corp reported first quarter of 2023 ended March 31, 2023 results: revenue $14.5 million, EPS $0.42 per share. Guidance reaffirmed.","evidence_excerpt":"invasive treatments for lung disease, today reported financial results for the first quarter of 2023 ended March 31, 2023. Recent Highlights • Recorded worldwide revenue of $14.5 million in the first quarter of 2023, a 35% increase over the same period last year and an increase of 37% on a constant currency basis • Delivered $9.3 million in U.S. revenue in the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1127537/000112753723000014/0001127537-23-000014-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2023 ended March 31, 2023"},{"label":"Revenue","value":"$14.5 million"},{"label":"EPS","value":"$0.42 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}